Strategies to optimize the promise of checkpoint-targeted anti-cancer therapy

References

• O'Donnell JS, Teng MWL, Smyth MJ. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat Rev Clin Oncol. 2019;16(3):151–167. doi:10.1038/s41571-018-0142-8
   PubMed Web of Science ®Google Scholar
• Tie Y, Tang F, Wei YQ, et al. Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets. J Hematol Oncol. 2022;15(1):61. doi:10.1186/s13045-022-01282-8
   PubMed Web of Science ®Google Scholar
• Roy R, Singh SK, Misra S. Advancements in cancer immunotherapies. Vaccines (Basel). 2022;11(1):59. doi:10.3390/vaccines11010059
   PubMed Web of Science ®Google Scholar
• Rapoport BL, Nayler S, Mlecnik B, et al. Tumor-infiltrating lymphocytes (TILs) in early breast cancer patients: High CD3+, CD8+, and immunoscore are associated with a pathological complete response. Cancers (Basel). 2022;14(10):2525. doi:10.3390/cancers14102525
   PubMed Web of Science ®Google Scholar
• van Dorp J, van der Heijden MS. The bladder cancer immune micro-environment in the context of response to immune checkpoint inhibition. Front Immunol. 2023;14:1235884. doi:10.3389/fimmu.2023.1235884
   PubMed Web of Science ®Google Scholar
• Fountzilas E, Vo HH, Mueller P, et al. Correlation between biomarkers and treatment outcomes in diverse cancers: a systematic review and meta-analysis of Phase I and II immunotherapy clinical trials. Eur J Cancer. 2023;189:112927. doi:10.1016/j.ejca.2023.05.015
   PubMed Web of Science ®Google Scholar
• Carlino F, Diana A, Piccolo A, et al. Immune-based therapy in triple-negative breast cancer: from molecular biology to clinical practice. Cancers (Basel). 2022;14(9):2102. doi:10.3390/cancers14092102
   PubMed Web of Science ®Google Scholar
• Gu D, Ao X, Yang Y, et al. Soluble immune checkpoints in cancer: production, function and biological significance. J Immunother Cancer. 2018;6(1):132. doi:10.1186/s40425-018-0449-0
   PubMedGoogle Scholar
• Ibrahim R, Saleh K, Chahine C, et al. LAG-3 inhibitors: novel immune checkpoint inhibitors changing the landscape of immunotherapy. Biomedicines. 2023;11(7):1878. doi:10.3390/biomedicines11071878
   PubMed Web of Science ®Google Scholar
• Bruss C, Kellner K, Albert V, et al. Immune checkpoint profiling in humanized breast cancer mice revealed cell-specific LAG-3/PD-1/TIM-3 co-expression and elevated PD-1/TIM-3 secretion. Cancers (Basel). 2023;15(9):2615. doi:10.3390/cancers15092615
   PubMed Web of Science ®Google Scholar
• Huseni MA, Wang L, Klementowicz JE, et al. CD8+ T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy. Cell Rep Med. 2023;4(1):100878. doi:10.1016/j.xcrm.2022.100878
   PubMedGoogle Scholar
• Liu C, Liu R, Wang B, et al. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer. J Immunother Cancer. 2021;9(1):e001895. doi:10.1136/jitc-2020-001895
   PubMed Web of Science ®Google Scholar
• van den Bulk J, de Miranda NFCC, Ten Dijke P. Therapeutic targeting of TGF-β in cancer: hacking a master switch of immune suppression. Clin Sci (Lond). 2021;135(1):35–52. doi:10.1042/CS20201236
   PubMed Web of Science ®Google Scholar
• Derosa L, Hellmann MD, Spaziano M, et al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann Oncol. 2018;29(6):1437–1444. doi:10.1093/annonc/mdy103
   PubMed Web of Science ®Google Scholar
• He R, Zhao X, Liu J, et al. PD-1 and CTLA-4 inhibitors in combination vs. alone for the treatment of advanced melanoma: a systematic review and meta-analysis. Med (Baltimore). 2022;101(41):e30561. doi:10.1097/MD.0000000000030561
   PubMed Web of Science ®Google Scholar
• Tawbi HA, Schadendorf D, Lipson EJ, et al. RELATIVITY-047 Investigators. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med. 2022;386(1):24–34. doi:10.1056/NEJMoa2109970
   PubMed Web of Science ®Google Scholar
• Davidson TM, Foster N, Lucien F, et al. Rescuing Cancer Immunity by Plasma Exchange in Metastatic Melanoma (ReCIPE-M1): protocol for a single-institution, open-label safety trial of plasma exchange to clear sPD-L1 for immunotherapy. BMJ Open. 2022;12(5):e050112. doi:10.1136/bmjopen-2021-050112
   PubMed Web of Science ®Google Scholar
• Orme JJ, Enninga EAL, Lucien-Matteoni F, et al. Therapeutic plasma exchange clears circulating soluble PD-L1 and PD-L1-positive extracellular vesicles. J Immunother Cancer. 2020;8(2):e001113. doi:10.1136/jitc-2020-001113
   PubMed Web of Science ®Google Scholar
• Hashemian SM, Shafigh N, Afzal G, et al. Plasmapheresis reduces cytokine and immune cell levels in COVID-19 patients with acute respiratory distress syndrome (ARDS). Pulmonology. 2021;27(6):486–492. doi:10.1016/j.pulmoe.2020.10.017
   PubMed Web of Science ®Google Scholar
• Porosnicu TM, Sirbu IO, Oancea C, et al. The impact of therapeutic plasma exchange on inflammatory markers and acute phase reactants in patients with severe SARS-CoV-2 infection. Medicina (Kaunas). 2023;59(5):867. doi:10.3390/medicina59050867
   PubMed Web of Science ®Google Scholar
• Xin Y, Shen G, Zheng Y, et al. Immune checkpoint inhibitors plus neoadjuvant chemotherapy in early triple-negative breast cancer: a systematic review and meta-analysis. BMC Cancer. 2021;21(1):1261. doi:10.1186/s12885-021-08997-w
   PubMed Web of Science ®Google Scholar
• Ji Q, Ding J, Hao M, et al. Immune checkpoint inhibitors combined with chemotherapy compared with chemotherapy alone for triple-negative breast cancer: a systematic review and meta-analysis. Front Oncol. 2021;11:795650. doi:10.3389/fonc.2021.795650
   PubMedGoogle Scholar
• Anderson R, Rapoport BL, Steel HC, et al. Pro-tumorigenic and thrombotic activities of platelets in lung cancer. Int J Mol Sci. 2023;24(15):11927. doi:10.3390/ijms241511927
   PubMed Web of Science ®Google Scholar
• Sasikumar PG, Ramachandra M. Small molecule agents targeting PD-1 checkpoint pathway for cancer immunotherapy: mechanisms of action and other considerations for their advanced development. Front Immunol. 2022;13:752065. doi:10.3389/fimmu.2022.752065
   PubMed Web of Science ®Google Scholar
• Hanson A, Elpek K, Duong E, et al. ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical models. PLoS ONE. 2020;15(9):e0239595. doi:10.1371/journal.pone.0239595
   PubMed Web of Science ®Google Scholar
• Yap TA, Gainor JF, Callahan MK, et al. First-in-Human Phase I/II ICONIC Trial of the ICOS agonist vopratelimab alone and with nivolumab: ICOS-high CD4 T-cell populations and predictors of response. Clin Cancer Res. 2022;28(17):3695–3708. doi:10.1158/1078-0432.CCR-21-4256
   PubMed Web of Science ®Google Scholar